Watchful waiting still viable option for follicular lymphoma Healio The aim was to identify parameters for initiating treatment in the rituximab (Rituxan, Genentech/Idec Pharmaceuticals) era and to determine how parameters for a watchful waiting strategy affected outcomes. Eighty percent of the patients had ... |
